Record Revenue Growth
Tenon Medical achieved record revenue of $1,200,000 for the third quarter of 2025, marking a 32% increase compared to the same period last year.
Successful Integration of SciVantage Acquisition
The integration of the SciVantage portfolio contributed meaningfully to top-line growth, with key members of the CyVantage leadership team joining Tenon, enhancing commercial execution and innovation.
Launch of Catamaran SE System
The full commercial launch of the Catamaran SE SI joint fusion system expanded the implant portfolio and strengthened Tenon's competitive position in the sacroiliac joint fusion market.
FDA Clearance for Symmetry Plus System
Achieved FDA 510(k) clearance for the Symmetry Plus SI joint fusion system, introducing advancements like 3D printed titanium implants and a simplified bone graft delivery system.
Strong Clinical Data
Clinical trials showed statistically significant improvements in pain and disability scores, with 83% of patients showing evidence of fusion and high satisfaction rates.
Improved Financial Metrics
Gross profit for the quarter was $800,000, or 66% of revenue, compared to $400,000, or 47%, in the prior year quarter, with no outstanding debt by the quarter's end.